Editor’s Pick: Clinical Management of Fibromyalgia and the Continuum of Polysymptomatic Distress Disorders

Editor’s Pick: Clinical Management of Fibromyalgia and the Continuum of Polysymptomatic Distress Disorders

August 23, 2016 at 8:24 AM 0 comments

In this specially selected article, Fleming gives a fascinating insight into the controversial field of fibromyalgia and polysymptomatic distress disorders. These conditions present with a diverse array of symptoms posing diagnostic challenges which many clinicians will face at some point in their career. The unifying central sensitisation theory discussed providesRead More

Avanafil: The Second-Generation Treatment of Erectile Dysfunction

Avanafil: The Second-Generation Treatment of Erectile Dysfunction

August 23, 2016 at 8:23 AM 0 comments

*Giovanni Corona,1 Mario Maggi,2 Emmanuele A. Jannini2,3 1. Endocrinology Unit 1, Maggiore-Bellaria Hospital, Medical Department, Azienda-Usl Bologna, Bologna, Italy 2. Sexual Medicine and Andrology Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy 3. Endocrinology, Andrology, and Medical Sexology, Department of Systems Medicine, University of RomeRead More

New Evidence for Exogenous Glycosaminoglycans Treatment of ‘Cystitis': Is the Future Now?

New Evidence for Exogenous Glycosaminoglycans Treatment of ‘Cystitis': Is the Future Now?

August 23, 2016 at 8:22 AM 0 comments

*Massimo Lazzeri,1 Philip Van Kerrebroeck2 1. Department of Urology, Istituto Clinico Humanitas IRCCS, Humanitas Clinical and Research Center, Rozzano, Milan, Italy 2. Department of Urology, Maastricht University Medical Center, Maastricht, Netherlands *Correspondence to massimo.lazzeri@humanitas.it Disclosure: The authors have declared no conflicts of interests. Received: 04.07.16 Accepted: 25.07.16 Support: The publicationRead More

The Evolving Biosimilar Landscape: Approval of the First Etanercept Biosimilar in Europe, An Interview With Emilio Martín-Mola

The Evolving Biosimilar Landscape: Approval of the First Etanercept Biosimilar in Europe, An Interview With Emilio Martín-Mola

August 23, 2016 at 8:21 AM 0 comments

*Caroline Charles Scilink Medical Writing, Biarritz, France. *Correspondence to scilink.mw@gmail.com Disclosure: Professor Martín-Mola has received funding from Biogen, Roche, MSD, UCB, and Sanofi. Support: Biogen provided funding for medical writing support in the development of this article. Biogen reviewed the article for medical accuracy and provided feedback to the authors.Read More

Late and Very Late Stent Thrombosis in the Era of Second-Generation Drug-Eluding Stents

Late and Very Late Stent Thrombosis in the Era of Second-Generation Drug-Eluding Stents

August 23, 2016 at 8:20 AM 0 comments

Jaya Mallidi, *Amir Lotfi Division of Cardiology, Baystate Medical Center, Tufts University, Springfield, Massachusetts, USA *Correspondence to amir.lotfi@bhs.org Disclosure: The authors have declared no conflicts of interest. Received: 24.11.15 Accepted: 10.03.16 Citation: EMJ. 2016;1[3]:85-93. Abstract Stent thrombosis is a life-threatening complication of percutaneous coronary intervention that often results in ST-segmentRead More

Spondyloarthritis: Pathogenesis, Clinical Manifestations, Diagnosis and Management

Spondyloarthritis: Pathogenesis, Clinical Manifestations, Diagnosis and Management

August 23, 2016 at 8:19 AM 0 comments

*Pilar S. del Río-Martínez Hospital Clínico Universitario “Lozano Blesa”, Zaragoza, Spain *Correspondence to psdelrio@yahoo.es Disclosure: The author has declared no conflicts of interest. Received: 25.01.16 Accepted: 28.06.16 Citation: EMJ. 2016;1[3]:96-102. Abstract The term spondyloarthritis (SpA) is used to describe a heterogeneous group of diseases sharing certain characteristics. Traditionally, patients withRead More

Evaluation of Stress Urinary Incontinence: State-of-the-Art Review

Evaluation of Stress Urinary Incontinence: State-of-the-Art Review

August 23, 2016 at 8:18 AM 0 comments

Dominic Lee,1 *Philippe E. Zimmern2 1. Department of Urology, St George Hospital, Kogarah, New South Wales, Australia 2. Department of Urology, University of Texas Southwestern Medical Center, Dallas, Texas, USA *Correspondence to philippe.zimmern@utsouthwestern.edu Disclosure: The authors have declared no conflicts of interest. Received: 04.01.16 Accepted: 29.02.16 Citation: EMJ. 2016;1[3]:103–110. AbstractRead More

Cirrhosis: Reviewing the Literature and Future Perspectives

Cirrhosis: Reviewing the Literature and Future Perspectives

August 23, 2016 at 8:17 AM 0 comments

*Xavier Verhelst, Anja Geerts, Hans Van Vlierberghe Department of Hepatology and Gastroenterology, Ghent University Hospital, Ghent, Belgium *Correspondence to xavier.verhelst@uzgent.be Disclosure: The authors have declared no conflicts of interest. Received: 07.01.16 Accepted: 09.02.16 Citation: EMJ. 2016;1[3]:111-117. Abstract Cirrhosis is the final stage of chronic liver disease and has many causes,Read More

In-Stent Restenosis After Carotid Artery Stenting: From Diagnosis to Treatment

In-Stent Restenosis After Carotid Artery Stenting: From Diagnosis to Treatment

August 23, 2016 at 8:16 AM 0 comments

*Giuseppe Di Gioia, Domenico Scordino, Cosimo Marco Campanale, Marco Miglionico, Antonio Creta, Claudio Proscia, Laura Ragni, Iginio Colaiori, Germano Di Sciascio Department of Medicine and Surgery, Unit of Cardiology, Campus Bio-Medico University of Rome, Rome, Italy *Correspondence to dottgiuseppedigioia@gmail.com Disclosure: The authors have declared no conflicts of interest. Received: 12.02.2016Read More

Hepatitis C: Is Regression of Advanced Fibrosis Possible After Treatment?

Hepatitis C: Is Regression of Advanced Fibrosis Possible After Treatment?

August 23, 2016 at 8:15 AM 0 comments

*Federico Sáez-Royuela, Ester Badia Department of Gastroenterology and Hepatology, Hospital Universitario de Burgos, Burgos, Spain *Correspondence to fsroyuela@gmail.com Disclosure: Federico Sáez-Royuela has received lecturing fees from Janssen-Cilag S.A. and Merck Sharp & Dhome Corp. Ester Badia has received lecturing fees from Janssen-Cilag S.A. and Gilead Sciences, S.L. Received: 22.01.16 Accepted:Read More